Janssen returns rights for experimental cancer immunotherapy to Alligator Bioscience, sending shares spiraling by 40%

Janssen has decided to hand back the rights to an experimental CD40 agonistic antibody to Alligator Bioscience as it reassesses its research priorities, sending the latter’s shares tumbling by 40%.